The phase 1 trial was designed to test the safety and dosage of the compound CuATSM. Results presented in the poster supports the establishment of a randomised, placebo controlled phase 2 study to further test this potential therapeutic.
Although results are promising CuATSM will need to be tested on more people in order to look at its effect on the progression of MND. We are hopeful that a phase 2 trial will commence later in 2019 or early 2020 and will be sure to keep the MND community up to date as more information becomes available.
We all hope for the day when any person diagnosed with MND can be prescribed a drug that will stop the disease in its tracks. Copper-ATSM may one day prove to be that drug, but we’re not there yet.
More information and updates on copper-ATSM can be found on the links below:
Spotlight on MND - MND Australia's blog features the latest update from Associate Professor Peter Crouch
Further discussion of the phase 1 trial for copper-ATSM can be found on the MND Association of England, Wales and Northern Ireland’s Research Blog
The website for the drug company running the copper-ATSM clinical trials is: www.colmeddev.com and their original press release is here
Click link here and download the pdf to see poster number CLT – 26 presented at the International ALS/MND Symposium last December which outlines the results of the Phase 1 trial.
Information on the development of Copper-ATSM, the work of Associate Professor Peter Crouch and his team to date and how supporters of the MND Research Institute of Australia have helped advance the development of this compound over the last 15 years is on the MND Australia website here.
For updates on this trial and other trials being conducted in Australia and overseas see the Clinical Trial page on our website and the Clinical Trials website
For more information listen to 2GB interview with Professor Dominic Rowe and Associate Professor Peter Crouch here.
ALS Untangled report #43: copper